The dilemma on the need for hormonal therapy in the salvage radiation setting after radical prostatectomy is a major one in current clinical practice, driven by the modest survival benefits seen in the RTOG 9601 trial with 2 years of bicalutamide (Shipley et al., PMID 28146658), but also follow up s...

Excellent and thorough answer by @Andrew J. Armstrong above. I would also just add the results of RTOG 0534/ [SPPORT] as corroboration, which looked at the benefit of adding 4-6 months of STADT using an anti-androgen + LHRH agonist in 2 of the three arms: Prostate bed RT alone, prostate bed RT + STA...